ABSTRACT
Symptoms of irritable bowel syndrome (IBS) have a profound impact on quality of life for many patients and current treatments are sometimes unsatisfactory. This controlled pilot study was conducted to evaluate effects of the proprietary GanedenBC(30) (Bacillus coagulans GBI-30, 6086) probiotic on IBS symptoms, in a randomized, double-blind, placebo-controlled clinical trial including patients with diarrhea-predominant IBS (IBS-D). Patients were randomized to receive either B. coagulans GBI-30, 6086 or placebo once a day for 8 weeks. Patients filled out a quality-of-life questionnaire, and self-assessment diaries were provided to record stool count and consistency, symptom severity, and medication consumption. Of the 61 patients enrolled, six did not meet the inclusion criteria and three were lost to follow-up. Of the remaining 52 patients with IBS-D, the average number of bowel movements per day was significantly reduced for patients treated with B. coagulans GBI-30, 6086 when compared to placebo (P = 0.042). Large variability in baseline scores prevented the assessment of severity scores and quality of life. This small pilot study provides evidence that the proprietary B. coagulans GBI-30, 6086 probiotic is safe and effective for reducing daily bowel movements in patients with IBS-D.
Subject(s)
Bacillus/chemistry , Irritable Bowel Syndrome/therapy , Probiotics/therapeutic use , Adolescent , Adult , Aged , Double-Blind Method , Female , Humans , Irritable Bowel Syndrome/physiopathology , Male , Middle Aged , Pilot Projects , Probiotics/adverse effects , Quality of Life , Severity of Illness Index , Surveys and Questionnaires , Treatment Outcome , Young AdultABSTRACT
Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis. After cessation of the sulfasalazine and completion of a six-week course of corticosteroids, these problems resolved over a period of four to six months. It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms. Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.
Subject(s)
Lupus Erythematosus, Systemic/chemically induced , Sulfasalazine/adverse effects , Adult , Antibodies, Antinuclear/analysis , Cardiac Tamponade/chemically induced , Colitis, Ulcerative/drug therapy , Humans , Male , Pleural Effusion/chemically induced , Pneumonia/chemically induced , Sulfasalazine/therapeutic useSubject(s)
Bacterial Infections/etiology , Parenteral Nutrition, Total , Aged , Aged, 80 and over , Bacillus/isolation & purification , Drug Contamination , Hospitals, Community , Hospitals, General , Humans , Middle Aged , Parenteral Nutrition, Total/standards , Staphylococcus epidermidis/isolation & purification , Streptococcus/isolation & purificationABSTRACT
A 66-year-old man had intrahepatic biliary papillomatosis. This benign tumor has great growth potential that can present a difficult management problem.